| Genentech, Inc. |
Level II |
10 | 29 |
$127,544 |
| Genentech, Inc. |
Level III |
5 | 5 |
$148,678 |
| Genentech, Inc. |
Level I |
4 | 4 |
$103,400 |
| Gilead Sciences, Inc. |
Level II |
4 | 4 |
$159,360 |
| Gilead Sciences, Inc. |
Level IV |
4 | 4 |
$184,160 |
| Buck Institute for Research on Aging |
Level III |
3 | 3 |
$114,130 |
| Buck Institute for Research on Aging |
Level IV |
2 | 2 |
$131,019 |
| Exelixis, Inc. |
Level II |
2 | 2 |
$149,662 |
| Genentech, Inc. |
Level IV |
2 | 2 |
$222,400 |
| Neuralink Corp. |
Level III |
2 | 2 |
$163,316 |
| Science Corporation |
Level II |
2 | 2 |
$148,689 |
| Synthego Holdings LLC |
Level II |
2 | 2 |
$146,000 |
| UNLEARN.AI, INC. |
Level III |
2 | 2 |
$148,720 |
| Washington Township Healthcare District |
Level IV |
2 | 2 |
$208,166 |
| AbbVie Inc. |
Level I |
1 | 1 |
$109,765 |
| AbbVie Inc. |
Level III |
1 | 1 |
$150,000 |
| AbbVie Biotherapeutics Inc. |
Level III |
1 | 1 |
$164,147 |
| ABBVIE BIOTHERAPEUTICS INC. |
Level IV |
1 | 1 |
$181,000 |
| Amgen Inc. |
Level I |
1 | 1 |
$142,900 |
| Amgen Inc. |
Level III |
1 | 1 |
$211,114 |
| Amgen Inc. |
Level IV |
1 | 1 |
$211,114 |
| Animate Biosciences, Inc. |
Level II |
1 | 1 |
$126,942 |
| Arcus Biosciences, Inc. |
Level II |
1 | 1 |
$147,000 |
| Arcus Biosciences, Inc. |
Level IV |
1 | 1 |
$178,200 |
| Ardelyx, Inc. |
Level II |
1 | 1 |
$125,278 |
| BeOne Medicines USA, Inc. |
Level IV |
1 | 1 |
$349,368 |
| BioCheck, Inc. |
Level I |
1 | 1 |
$120,000 |
| Blueprint Medicines Corporation |
Level IV |
1 | 1 |
$208,822 |
| Buck Institute for Research on Aging |
Level I |
1 | 1 |
$80,350 |
| Cerus Corporation |
Level III |
1 | 1 |
$148,678 |
| Coherence Neuro Global, Inc. |
Level II |
1 | 1 |
$125,278 |
| Conception Biosciences, Inc. |
Level II |
1 | 1 |
$140,000 |
| Coopervision, Inc. |
Level I |
1 | 1 |
$101,858 |
| Dren Bio Management, Inc. |
Level II |
1 | 1 |
$155,000 |
| Eli Lilly and Company |
Level IV |
1 | 1 |
$216,480 |
| Epia Neuro, Inc. |
Level II |
1 | 1 |
$196,500 |
| ETEAM INC. |
Level I |
1 | 1 |
$107,973 |
| Eureka Therapeutics, Inc. |
Level II |
1 | 1 |
$130,000 |
| Exelixis, Inc. |
Level IV |
1 | 1 |
$216,000 |
| Generate Biomedicines, Inc. |
Level I |
1 | 1 |
$101,858 |
| Gilead Sciences, Inc. |
Level I |
1 | 1 |
$119,360 |
| Gilead Sciences, Inc. |
Level III |
1 | 1 |
$159,360 |
| Horizon Therapeutics USA, Inc. |
Level I |
1 | 1 |
$150,075 |
| Horizon Therapeutics USA, Inc. |
Level IV |
1 | 1 |
$173,745 |
| Immuneering Corporation |
Level III |
1 | 1 |
$250,000 |
| Janssen Research & Development, LLC |
Level IV |
1 | 1 |
$172,099 |
| Kardigan, Inc. |
Level III |
1 | 1 |
$150,000 |
| Kite Pharma Inc. |
Level I |
1 | 1 |
$119,360 |
| Kite Pharma Inc. |
Level II |
1 | 1 |
$125,278 |
| Muse Bio, Inc. |
Level IV |
1 | 1 |
$172,099 |
| Neurona Therapeutics, Inc. |
Level III |
1 | 1 |
$150,000 |
| Northern California Institute for Research and Education |
Level II |
1 | 1 |
$97,240 |
| Novartis Institutes for BioMedical Research, Inc. |
Level II |
1 | 1 |
$125,278 |
| Nudge Workbench OpCo, LLC |
Level I |
1 | 1 |
$101,858 |
| Retro Biosciences, Inc. |
Level II |
1 | 1 |
$177,465 |
| Seer, Inc. |
Level II |
1 | 1 |
$125,278 |
| SIMULATIONS PLUS, INC. |
Level III |
1 | 1 |
$190,000 |
| Sutro Biopharma, Inc. |
Level III |
1 | 1 |
$162,137 |
| University of California, San Francisco |
Level II |
1 | 1 |
$148,900 |
| Arsenal Biosciences, Inc. |
Level III |
1 | 1 |
$140,462 |
| Genentech, Inc. |
Level I |
1 | 1 |
$99,715 |
| University of California, San Francisco |
not stated |
31 | 31 |
$93,200 |
| University of California, Berkeley |
not stated |
7 | 7 |
$89,000 |